Several mechanisms have been proposed underlying both the innate and acquired resistance of MM to various therapies, which include the activation of survival/anti-apoptotic pathways, such as the PI3K/AKT, JAK/STAT3, TGFβ/β-catenin, Wnt, Notch, IGF, and NF-κB pathways [3–10]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.